News und Analysen
![Why CRISPR Therapeutics Stock Charged Northward This Week: https://g.foolcdn.com/editorial/images/753665/biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGJJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6cf16e57a7261db2be0f6e0b294c948793acbb9e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech.jpg?locale=de)
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days
![Why CRISPR Therapeutics Stock Charged Northward This Week: https://g.foolcdn.com/editorial/images/753665/biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGJJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6cf16e57a7261db2be0f6e0b294c948793acbb9e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech.jpg?locale=de)
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days
![Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA: https://g.foolcdn.com/editorial/images/753319/biotech-pharma-researchers-talk-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemJJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aecc3508e5d7de9d8d7a65e533b7d27ea45ea6d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech-pharma-researchers-talk-lab.jpg?locale=de)
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about
![Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA: https://g.foolcdn.com/editorial/images/753319/biotech-pharma-researchers-talk-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemJJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aecc3508e5d7de9d8d7a65e533b7d27ea45ea6d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech-pharma-researchers-talk-lab.jpg?locale=de)
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about
![Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA: https://g.foolcdn.com/editorial/images/753319/biotech-pharma-researchers-talk-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemJJYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aecc3508e5d7de9d8d7a65e533b7d27ea45ea6d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech-pharma-researchers-talk-lab.jpg?locale=de)
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about
![Is Novocure Stock a Buy?: https://g.foolcdn.com/editorial/images/752915/cancer-patient-flexing-muscle.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0xIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ad8f30cb36b2f2c8d8edd75d783fe323455717b9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cancer-patient-flexing-muscle.jpg?locale=de)
Is Novocure Stock a Buy?
Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it.
Medical device specialist
![Is AbbVie Stock a Buy Now?: https://g.foolcdn.com/editorial/images/753323/a-young-scientist-recording-her-findings-on-a-tablet.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGpIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--664466a2b03c2c1ce06065774b18ad3ed5bf49f0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-young-scientist-recording-her-findings-on-a-tablet.jpg?locale=de)
Is AbbVie Stock a Buy Now?
With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. To
![Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q3 2023 Earnings CallNov 02, 2023, 4:30 p.m. ET
Operator
Source Fool.com
![There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?: https://g.foolcdn.com/editorial/images/753464/gettyimages-1199696916.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOG5IYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ec4743807aeea8b08d2a2efb12ad1bf352035d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1199696916.jpg?locale=de)
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
It may seem difficult to get excited about Pfizer (NYSE: PFE) these days. After the company brought in record revenue of $100 billion last year thanks to its coronavirus vaccine, Comirnaty, and its
![There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?: https://g.foolcdn.com/editorial/images/753464/gettyimages-1199696916.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOG5IYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ec4743807aeea8b08d2a2efb12ad1bf352035d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1199696916.jpg?locale=de)
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
It may seem difficult to get excited about Pfizer (NYSE: PFE) these days. After the company brought in record revenue of $100 billion last year thanks to its coronavirus vaccine, Comirnaty, and its
![Geron (GERN) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Geron (GERN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET
Operator
Source Fool.com
![Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q3 2023 Earnings CallNov 02, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Zoetis (ZTS) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q3 2023 Earnings CallNov 02, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![Cigna Group (CI) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Cigna Group (CI) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Cigna Group (NYSE: CI)Q3 2023 Earnings CallNov 02, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![1 Stock Down 15% This Year to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/752478/physicians-in-an-operating-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWJHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--83521867f7ceb6ef62322b78f1aab987d0163756/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physicians-in-an-operating-room.jpg?locale=de)
1 Stock Down 15% This Year to Buy and Hold Forever
The past three years have been a roller coaster for Abbott Laboratories (NYSE: ABT). The healthcare giant dealt with a slowdown in its medical device business caused by the pandemic, fluctuating
![This High-Yield Dividend Stock Is a Proven Wealth Creator: https://g.foolcdn.com/editorial/images/753306/growth-stock.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXZHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--86d98aa9a87e64e7d5c3aac635f3b6ff999c9ef5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-stock.jpg?locale=de)
This High-Yield Dividend Stock Is a Proven Wealth Creator
Found in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. The pharmaceutical titan has been one of the best-performing stocks since the end of World War II
![This High-Yield Dividend Stock Is a Proven Wealth Creator: https://g.foolcdn.com/editorial/images/753306/growth-stock.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXZHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--86d98aa9a87e64e7d5c3aac635f3b6ff999c9ef5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-stock.jpg?locale=de)
This High-Yield Dividend Stock Is a Proven Wealth Creator
Found in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. The pharmaceutical titan has been one of the best-performing stocks since the end of World War II
![Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?: https://g.foolcdn.com/editorial/images/752772/scientists-working-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXJHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--018c728e2b4f7c0263c2447d5a908643b33f43ec/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-working-in-a-lab.jpg?locale=de)
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no
![2 Growth Stocks That Could Help Set You Up for Life: https://g.foolcdn.com/editorial/images/753185/investing-woman-wall-street-suit-stocks-finance-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXpHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48174cfb19e32544f8f40d53003804ef8186f99d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investing-woman-wall-street-suit-stocks-finance-1.jpg?locale=de)
2 Growth Stocks That Could Help Set You Up for Life
The stock market has tested even the most resilient of investors over the last two years, as bouts of volatility followed by surges across multiple sectors have become common. That's why most
![2 Growth Stocks That Could Help Set You Up for Life: https://g.foolcdn.com/editorial/images/753185/investing-woman-wall-street-suit-stocks-finance-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXpHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48174cfb19e32544f8f40d53003804ef8186f99d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investing-woman-wall-street-suit-stocks-finance-1.jpg?locale=de)
2 Growth Stocks That Could Help Set You Up for Life
The stock market has tested even the most resilient of investors over the last two years, as bouts of volatility followed by surges across multiple sectors have become common. That's why most
![3 Dividend Stocks That Can Power Your Portfolio for Decades: https://g.foolcdn.com/editorial/images/752769/a-couple-looking-at-a-tablet-during-breakfast.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi9HYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c62d7f9affa7fb979e62dda02b6e371be3297d6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-looking-at-a-tablet-during-breakfast.jpg?locale=de)
3 Dividend Stocks That Can Power Your Portfolio for Decades
Holding some top dividend stocks in your portfolio can help you generate recurring income for years. This can bolster your savings for retirement or just give you extra money to help pay bills while
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
![1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years: https://g.foolcdn.com/editorial/images/753225/growth-trend.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3ZGYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a8c96007f436c9c13a504c2f09ea8923651f415a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-trend.jpg?locale=de)
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
The pharmaceutical industry has been a source of extraordinary returns for investors who have picked the right stocks. Since the end of World War II, five of the top 30 performers in the U.S. stock
![1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years: https://g.foolcdn.com/editorial/images/753225/growth-trend.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3ZGYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a8c96007f436c9c13a504c2f09ea8923651f415a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-trend.jpg?locale=de)
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
The pharmaceutical industry has been a source of extraordinary returns for investors who have picked the right stocks. Since the end of World War II, five of the top 30 performers in the U.S. stock